Biocon buys Viatris biosimilars for $3.3bn, eyes IPO
India’s Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its […]
India’s Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its […]
Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy Published: Nov 19, 2021 | Tags: Jazz, Sunosi, solriamfetol, […]
Shots: The companies launch Semglee and Insulin Glargine as interchangeable biosimilars products to improve patients’ access with type 1 & 2 diabetes. Biocon and Viatris […]
Generic medicines are the backbone of the healthcare system. The expiry of patents of branded drugs is the essential tool in the development of generic […]
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective […]
Roche Publishes the Results of Evrysdi (risdiplam) in FIREFISH Study to Treat of Type 1 SMA at NEJM Published: July 30, 2021 | Tags: Roche, […]
Shots: The US FDA has approved Semglee (insulin glargine-yfgn injection) as the first interchangeable biosimilar product under the 351(k) regulatory pathways to treat diabetes Semglee […]
Shots: The companies collaborated for Adagio’s ADG20 for both the treatment & prevention of COVID-19 as monothx. or combination regimen Biocon will gain rights to […]
The first quarter of 2021 highlights new approvals, M&A, and the clinical data of COVID-19 vaccines. The companies expand their working in COVID-19 by targeting […]
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective […]
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective […]
Sinopharm’s COVID-19 Vaccine Demonstrates 79% Efficacy in P-III Study Published: Dec 30, 2020 | Tags: COVID-19, Interim Analysis, New Coronavirus Inactivated Vaccine, P-lll Study, reports, […]
Shots: The launch of Tacrolimus capsules follows the approval of the US FDA in Nov’20 and emphasizes Biocon activity to make affordable healthcare accessible Tacrolimus […]
Shots: The launch of Tacrolimus capsules follows from approval of US FDA in Nov. 2020 and underscores Biocon relentless pursuit to make affordable healthcare accessible […]
Shots: The two companies collaborated to develop and distribute innovative digital therapeutics supporting people with diabetes on biologics therapy. The collaboration allows Biocon to offer […]
Biocon has announced a deal with digital therapy specialist Voluntis, aiming to create personalised care for people with type 2 diabetes taking biosimilar insulins. The […]
1. Eli Lilly Reports Results of Mirikizumab in P-III OASIS-2 Study to Treat Moderate to Severe Plaque Psoriasis Published: Jul 17, 2020 | Tags: Eli Lilly, […]
Copyright © 2024 | WordPress Theme by MH Themes